Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ianalumab VAY736 given as a monthly injection under the skin for one year. This study focuses on adults with Sjgrens disease who experience a high level of symptoms. The trial is a Phase III, double-blind, randomized study comparing ianalumab to a placebo to assess how well it reduces symptoms and improves quality of life. Participants will receive either 300 mg of ianalumab or a placebo once a month by subcutaneous injection for 52 weeks. The study has two groups one receiving the active drug and the other receiving placebo injections. The aim is to see how ianalumab affects dryness symptoms and other disease-related measures compared to placebo during the treatment period. During the study, participants will be closely monitored with various assessments including symptom scores, saliva flow tests, and quality of life questionnaires over the 52 weeks. Researchers will track changes in oral dryness and other symptoms, fatigue, and overall well-being. Safety and side effects will be monitored throughout the treatment period, and participants will have regular visits for evaluations.